[go: up one dir, main page]

RU2011123762A - PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN, PSEUDOEPHEDRINE AND CHLORPHENIRAMINE - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN, PSEUDOEPHEDRINE AND CHLORPHENIRAMINE Download PDF

Info

Publication number
RU2011123762A
RU2011123762A RU2011123762/15A RU2011123762A RU2011123762A RU 2011123762 A RU2011123762 A RU 2011123762A RU 2011123762/15 A RU2011123762/15 A RU 2011123762/15A RU 2011123762 A RU2011123762 A RU 2011123762A RU 2011123762 A RU2011123762 A RU 2011123762A
Authority
RU
Russia
Prior art keywords
amount
range
composition according
composition
alkali metal
Prior art date
Application number
RU2011123762/15A
Other languages
Russian (ru)
Inventor
М. Берат БЕРАН
Original Assignee
Берко Иладж Ве Кимия Сан. А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берко Иладж Ве Кимия Сан. А.С. filed Critical Берко Иладж Ве Кимия Сан. А.С.
Publication of RU2011123762A publication Critical patent/RU2011123762A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Фармацевтическая композиция для облегчения симптомов гриппа, а также общей простуды, жара, синусита или заложенности носа, головной боли и общего недомогания, отличающаяся содержанием от 4 до 200 мг/мл ибупрофена, от 0,6 до 30 мг/мл псевдоэфедрина HCl, от 0,04 до 2 мг/мл хлорфенирамина малеата и соли щелочного металла или смеси солей щелочных металлов для поддержания уровня рН в конечной композиции между примерно 7 и примерно 9.2. Композиция по п.1, отличающаяся тем, что указанная соль щелочного металла представляет собой бикарбонат натрия.3. Композиция по п.2, отличающаяся тем, что указанная соль бикарбоната натрия содержится в количестве от 1,5 до 300 мг/мл.4. Композиция по п.1, отличающаяся тем, что указанную соль щелочного металла выбирают из группы, состоящей из гидроксида натрия, гидроксида калия, карбоната кальция, гидроксида магния или их смеси.5. Композиция по п.2, отличающаяся тем, что количество ибупрофена находится в пределах от 10 до 100 мг/мл, количество псевдоэфедрина HCl находится в пределах от 1 до 6 мг/мл, количество хлорфенирамина малеата находится в пределах от 0,1 до 1 мг/мл, а количество бикарбоната натрия находится в пределах от 6 до 30 мг/мл.6. Композиция по п.5, отличающаяся тем, что количество ибупрофена находится в пределах от 15 до 25 мг/мл, количество псевдоэфедрина HCl находится в пределах от 2 до 4 мг/мл, количество хлорфенирамина малеата находится в пределах от 0,15 до 0,25 мг/мл, а количество бикарбоната натрия находится в пределах от 16 до 20 мг/мл.7. Композиция по любому из предшествующих пунктов, отличающаяся тем, что указанная композиция дополнительно содержит глицерин, нипагин М-натрия, сахар, банановую эссенцию, красител1. A pharmaceutical composition for alleviating the symptoms of influenza, as well as a common cold, fever, sinusitis or nasal congestion, headache and general malaise, characterized by a content of 4 to 200 mg / ml ibuprofen, 0.6 to 30 mg / ml pseudoephedrine HCl, from 0.04 to 2 mg / ml of chlorpheniramine maleate and an alkali metal salt or a mixture of alkali metal salts to maintain the pH in the final composition between about 7 and about 9.2. The composition according to claim 1, characterized in that said alkali metal salt is sodium bicarbonate. The composition according to claim 2, characterized in that said sodium bicarbonate salt is contained in an amount of from 1.5 to 300 mg / ml. A composition according to claim 1, characterized in that said alkali metal salt is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium carbonate, magnesium hydroxide or a mixture thereof. The composition according to claim 2, characterized in that the amount of ibuprofen is in the range from 10 to 100 mg / ml, the amount of pseudoephedrine HCl is in the range from 1 to 6 mg / ml, the amount of chlorpheniramine maleate is in the range from 0.1 to 1 mg / ml, and the amount of sodium bicarbonate is in the range from 6 to 30 mg / ml. 6. The composition according to claim 5, characterized in that the amount of ibuprofen is in the range of 15 to 25 mg / ml, the amount of pseudoephedrine HCl is in the range of 2 to 4 mg / ml, the amount of chlorpheniramine maleate is in the range of 0.15 to 0, 25 mg / ml, and the amount of sodium bicarbonate is in the range of 16 to 20 mg / ml. 7. A composition according to any one of the preceding paragraphs, characterized in that said composition further comprises glycerin, M-sodium nipagin, sugar, banana essence, dye

Claims (9)

1. Фармацевтическая композиция для облегчения симптомов гриппа, а также общей простуды, жара, синусита или заложенности носа, головной боли и общего недомогания, отличающаяся содержанием от 4 до 200 мг/мл ибупрофена, от 0,6 до 30 мг/мл псевдоэфедрина HCl, от 0,04 до 2 мг/мл хлорфенирамина малеата и соли щелочного металла или смеси солей щелочных металлов для поддержания уровня рН в конечной композиции между примерно 7 и примерно 9.1. A pharmaceutical composition for alleviating the symptoms of influenza, as well as a common cold, fever, sinusitis or nasal congestion, headache and general malaise, characterized by a content of 4 to 200 mg / ml ibuprofen, 0.6 to 30 mg / ml pseudoephedrine HCl, from 0.04 to 2 mg / ml of chlorpheniramine maleate and an alkali metal salt or a mixture of alkali metal salts to maintain the pH in the final composition between about 7 and about 9. 2. Композиция по п.1, отличающаяся тем, что указанная соль щелочного металла представляет собой бикарбонат натрия.2. The composition according to claim 1, characterized in that said alkali metal salt is sodium bicarbonate. 3. Композиция по п.2, отличающаяся тем, что указанная соль бикарбоната натрия содержится в количестве от 1,5 до 300 мг/мл.3. The composition according to claim 2, characterized in that said sodium bicarbonate salt is contained in an amount of from 1.5 to 300 mg / ml. 4. Композиция по п.1, отличающаяся тем, что указанную соль щелочного металла выбирают из группы, состоящей из гидроксида натрия, гидроксида калия, карбоната кальция, гидроксида магния или их смеси.4. The composition according to claim 1, characterized in that said alkali metal salt is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium carbonate, magnesium hydroxide or a mixture thereof. 5. Композиция по п.2, отличающаяся тем, что количество ибупрофена находится в пределах от 10 до 100 мг/мл, количество псевдоэфедрина HCl находится в пределах от 1 до 6 мг/мл, количество хлорфенирамина малеата находится в пределах от 0,1 до 1 мг/мл, а количество бикарбоната натрия находится в пределах от 6 до 30 мг/мл.5. The composition according to claim 2, characterized in that the amount of ibuprofen is in the range from 10 to 100 mg / ml, the amount of pseudoephedrine HCl is in the range from 1 to 6 mg / ml, the amount of chlorpheniramine maleate is in the range from 0.1 to 1 mg / ml, and the amount of sodium bicarbonate is in the range from 6 to 30 mg / ml. 6. Композиция по п.5, отличающаяся тем, что количество ибупрофена находится в пределах от 15 до 25 мг/мл, количество псевдоэфедрина HCl находится в пределах от 2 до 4 мг/мл, количество хлорфенирамина малеата находится в пределах от 0,15 до 0,25 мг/мл, а количество бикарбоната натрия находится в пределах от 16 до 20 мг/мл.6. The composition according to claim 5, characterized in that the amount of ibuprofen is in the range of 15 to 25 mg / ml, the amount of pseudoephedrine HCl is in the range of 2 to 4 mg / ml, the amount of chlorpheniramine maleate is in the range of 0.15 to 0.25 mg / ml, and the amount of sodium bicarbonate is in the range from 16 to 20 mg / ml. 7. Композиция по любому из предшествующих пунктов, отличающаяся тем, что указанная композиция дополнительно содержит глицерин, нипагин М-натрия, сахар, банановую эссенцию, краситель Желтый Закат и деионизированную воду.7. A composition according to any one of the preceding paragraphs, characterized in that said composition further comprises glycerin, M-sodium nipagin, sugar, banana essence, Yellow Sunset dye and deionized water. 8. Композиция по п.7, отличающаяся тем, что указанная композиция находится в жидкой форме для перорального применения, включая сироп и формы водных суспензий.8. The composition according to claim 7, characterized in that the composition is in liquid form for oral use, including syrup and forms of aqueous suspensions. 9. Композиция по п.8, отличающаяся тем, что указанная жидкая форма для перорального применения также содержит шипучие таблетки, которые дают в результате композиции для перорального применения после их растворения в воде, а также формы саше, содержащие единичную дозу. 9. The composition of claim 8, wherein said oral liquid form also contains effervescent tablets, which result in an oral composition after dissolving in water, as well as a single dose dosage form.
RU2011123762/15A 2008-11-11 2009-03-30 PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN, PSEUDOEPHEDRINE AND CHLORPHENIRAMINE RU2011123762A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR200808511 2008-11-11
TR2008/08511 2008-11-11
PCT/TR2009/000046 WO2010056216A1 (en) 2008-11-11 2009-03-30 Pharmaceutical composition comprising ibuprofen, pseudoephedrine and chlorpheniramine

Publications (1)

Publication Number Publication Date
RU2011123762A true RU2011123762A (en) 2012-12-20

Family

ID=41055188

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011123762/15A RU2011123762A (en) 2008-11-11 2009-03-30 PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN, PSEUDOEPHEDRINE AND CHLORPHENIRAMINE

Country Status (4)

Country Link
CN (1) CN102264358A (en)
RU (1) RU2011123762A (en)
TR (1) TR201107202T1 (en)
WO (1) WO2010056216A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2965746B1 (en) 2014-07-10 2019-03-13 Santa Farma Ilaç Sanayi A.S. An oral pharmaceutical composition comprising ibuprofen, ibuprofen sodium dihydrate, pseudoephedrine hydrochloride and chlorpheniramine maleate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
CA2084028A1 (en) * 1991-11-27 1993-05-28 Harish B. Pandya Hot flu composition
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
KR100507771B1 (en) * 2002-11-08 2005-08-17 한미약품 주식회사 A composition for oral administration of water-insoluble anti-cold drug and a preparation method thereof
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
DE10359790A1 (en) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Effervescent preparation of a basic pharmaceutically active substance
WO2005063219A2 (en) * 2003-12-23 2005-07-14 Ranbaxy Laboratories Limited Ibuprofen-containing soft gelatin capsules
US8956652B2 (en) * 2005-09-15 2015-02-17 Tower Laboratories, Ltd. Effervescent rehydrating beverage tablet/granules
US20070110676A1 (en) * 2005-11-17 2007-05-17 The Procter & Gamble Company Compositions useful for prevention and treatment of common cold and influenza-like symptoms
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness

Also Published As

Publication number Publication date
WO2010056216A1 (en) 2010-05-20
CN102264358A (en) 2011-11-30
TR201107202T1 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
HRP20201685T1 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
RU2005115855A (en) COMPOSITION OF TRAMADOL PROLONGED BY RELEASE WITH 24 HOUR ACTION
RU2009125972A (en) SOLID DOSAGE FORMS, PROGESTIN, AND METHODS FOR PRODUCING AND APPLICATION OF THE INDICATED DOSED FORMS
RU2013126121A (en) COMPOSITIONS AND METHODS OF TREATING MYELOFIBROSIS
UA107174C2 (en) THE Crystalline Forms of Saxagliptin and the Process of Obtaining It (OPTIONS)
JP2010529999A5 (en)
RU2013136384A (en) COMPOSITION CONTAINING SODIUM-Glucose Inhibitors 1 and 2 Inhibitors, and Methods for Their Use
BR112015000088B1 (en) pharmaceutical compositions comprising rifamixin and amino acids, method of preparation and use thereof
ES2926494T3 (en) Combination of naproxen and fexofenadine to inhibit symptoms associated with veisalgia
WO2007005633A8 (en) Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
RU2006120946A (en) COMPOSITION OF PREGABALIN
DE602005024800D1 (en) COUGAR, LIQUID AND INGESTIONABLE TABLET WITH A CALCIUM-CONTAINING COMPOUND AS AN ACTIVE SUBSTANCE
RU2014142000A (en) L-sugar colon cleansing agent and its uses
RU2014149581A (en) Effervescent dosage form
JP2019533679A5 (en)
EA200702319A1 (en) PHARMACEUTICAL MEDICAL FORMS CONTAINING LIPID PHASE
RU2010151969A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PREMATURE EJACULATION
CN103251554A (en) Stable edaravone injection and preparation method thereof
RU2011123762A (en) PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN, PSEUDOEPHEDRINE AND CHLORPHENIRAMINE
JP2011516544A5 (en)
RU2007119641A (en) COMPOSITION INCLUDING ACETAMINOPHEN, CAFFEINE AND OPTIONAL ASPIRINE IN A MIXTURE WITH AN ALKALINE AGENT FOR INCREASING ABSORPTION
RU2014130743A (en) TABLETS AND DRY COATED PRODUCTS
PE20120122A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ANALGESIC AND VITAMINS
ES2507570T3 (en) Zn / trimethoprim combination therapy
RU2009131757A (en) OXALIPLATIN PHARMACEUTICAL COMPOSITION WITH A BUFFER BASED ON SUGAR ALCOHOL

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130918